MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2025.110831

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025

Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.

Zayed Sondos, Lang Pencilla, Read Nancy, Correa Rohann J M, Mutsaers Adam, Goodman Christopher D, D'Angelo Krista, Kieraszewicz Kelsey, Vanwynsberghe Danielle, Kingsbury-Paul Alika, Crewdson Kathlin, Neeb Jennifer, Carreau Caitlin, Winquist Eric, Kuruvilla Sara, Stewart Paul, Moulin Dwight E, Warner Andrew, Palma David A

СтатьяРандомизированное исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Radiation-induced mucositis (RIM) pain confers substantial morbidity for head and neck cancer (HNC) patients undergoing radiotherapy (RT) or chemoradiotherapy (CRT). With no well-established standard treatment, OPTIMAL-HN aimed to demonstrate the non-inferiority of multimodal analgesia (MMA; analgesic medications with different mechanisms of action) to opioid analgesia alone.

METHODS

OPTIMAL-HN (ClinicalTrials.gov identifier: NCT04221165) was an open-label, non-inferiority, randomized clinical trial. We enrolled HNC patients receiving curative-intent RT/CRT and experiencing moderate ≥ 4/10 RIM pain. We randomized 1:1, stratified by RT vs. CRT, to opioids alone (standard arm) or MMA (pregabalin, acetaminophen, naproxen, and opioids if required). The primary endpoint was mean pain score (range: 0-10) during the last week of RT. Secondary endpoints included mean weekly opioid use, duration of opioid requirement, quality of life, weight loss, and toxicity. All analyses were pre-specified, including testing for superiority if non-inferiority was demonstrated.

RESULTS

Forty-nine patients were enrolled, 25 in the opioid analgesia arm and 24 in the MMA arm. Median follow-up was 4.2 months. The primary endpoint, mean pain score during the last 7 days of RT, was 5.1 (95 % confidence interval [CI]: 4.1-6.1) in the opioid arm and 4.9 (95 % CI: 3.8-5.9) in the MMA arm (non-inferiority p = 0.039, superiority p = 0.72). Analyzing all pain scores from enrollment to 6-weeks post-RT, MMA demonstrated both non-inferiority and superiority compared to opioids alone (non-inferiority p = 0.0024, superiority p < 0.001). One patient in the MMA arm was admitted with acute kidney injury, possibly related to the analgesic regimen. Arms were similar for all other secondary endpoints.

CONCLUSIONS

MMA demonstrates non-inferiority to opioid analgesia alone in managing RIM pain during the last week of RT and superiority when analyzing the post-RT time period. MMA should, therefore, be considered an effective mode of analgesia for HNC patients receiving RT.

Для цитирования: Zayed Sondos, Lang Pencilla, Read Nancy, Correa Rohann J M, Mutsaers Adam, Goodman Christopher D, D'Angelo Krista, Kieraszewicz Kelsey, Vanwynsberghe Danielle, Kingsbury-Paul Alika, Crewdson Kathlin, Neeb Jennifer, Carreau Caitlin, Winquist Eric, Kuruvilla Sara, Stewart Paul, Moulin Dwight E, Warner Andrew, Palma David A. Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2025. DOI: 10.1016/j.radonc.2025.110831.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.